SVD-1

SVD-1 is an all-D-enantiomeric peptide ligand developed as a disease-modifying treatment for Parkinson's disease and other synucleinopathies. Discovered via mirror-image phage display against full-length alpha-synuclein (α-syn), SVD-1 exhibits picomolar binding affinity for α-syn. Its therapeutic mechanism involves the specific destabilization and disassembly of toxic α-syn oligomers into their physiological monomeric forms, thereby inhibiting de novo and seeded aggregation. Developed by researchers at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf, SVD-1 has demonstrated the ability to reduce intracellular seeding capacity and toxic effects in cell culture models, representing a novel approach to halting the prion-like progression of neurodegeneration.